Business Wire

IP Showcase Returns To IBC – More Partners and Products; Real-Time IP Is Here and Now

Del

The 2017 IP Showcase at IBC builds on the highly successful IP Interoperability Zone – a world-first at IBC2016 – with more companies demonstrating their IP products, and great strides having been made in formalising and universally adopting the SMPTE ST 2110 suite of real-time IP signal flow standards.

The IP Showcase is set to be a major destination for visitors to IBC2017 – demonstrating to the broadcast and media world that real-time IP production is a practical, flexible, efficient reality that is rapidly taking hold in mainstream operations. IP is no longer a “future” — it is here and now.

The partners behind the IP Showcase - AES, AIMS, AMWA, EBU, IABM, MNA, SMPTE, and VSF - have come together with IBC to deliver a one-stop destination where everyone from broadcast/IT engineers and CEOs to TV producers can learn everything they need to know to unlock the full potential of using IP for real-time media.

More than 40 vendors will work together to demonstrate real-world IP interoperability based on SMPTE ST 2110 final draft standards and AMWA NMOS specifications — a single set of common IP interop standards and specifications that are unleashing the flexibility and efficiency of IP in real-time media. To prove ease of use as well as interoperability, the demonstrations are divided into logical application pods — live production signal flows, contribution and playout signal flows, etc. — all shown under the control of familiar user interfaces.

Visitors to the IP Showcase will learn:

  • The business, technical, and creative benefits of IP workflows
  • The practical steps to take to unlock the benefits of using IP networks for real-time media
  • The knowledge, skills, and resources required
  • How others are already leveraging IP in real-world broadcaster applications
  • An understanding of the SMPTE ST 2110 suite of professional media over IP networks standards
  • What the future holds – including NMOS IS-05 Connection Management for IP-based media systems

The integrated IP Showcase theatre, curated by IABM, will be running a non-stop series of presentations covering the full gamut of knowledge for real-time IP production and intra-facility distribution. Visitors will hear about the rapidly increasing number of real-world IP deployments from broadcasters who have already embraced IP signal flows. They will also learn about the business and creative benefits of IP, and how these benefits can be applied to their own operations.

With no direct sales agenda, the IP Showcase is dedicated to educating and energising IBC visitors to embrace the change, plan effectively, and ultimately build a more flexible, more efficient and more creative broadcasting industry.

“IBC is excited to be working with our IP Showcase Partners once again at IBC2017,” said Michael Crimp, CEO, IBC. “The IP Showcase will be an ideal opportunity for our visitors to see how far the IP Interop standard has come since its original demonstration at IBC2016. They will also be able to learn from those who have already adopted IP as the norm”

Note to Editors:

About IBC

IBC is the world’s leading media, entertainment and technology show. It attracts 55,000+ attendees from more than 170 countries and combines a highly respected and peer-reviewed conference with an exhibition that showcases more than 1,700 leading suppliers of state of the art electronic media and entertainment technology.

IBC2017 Dates

Conference: 14 – 18 September 2017

Exhibition: 15 – 19 September 2017

For more information about IBC2017 visit: show.ibc.org

AES - The Audio Engineering Society is the only professional society devoted exclusively to audio technology. The AES is an international organisation that unites audio engineers, creative artists, scientists and students worldwide by promoting advances in audio and disseminating new knowledge and research.

The Alliance for IP Media Solutions (AIMS) - AIMS is a not-for-profit trade alliance formed "to foster the adoption of common, ubiquitous protocols for interoperability over IP". AIMS focuses its activities on the implementation and promotion of standards, recommendations and open specifications thus complementing the work of the JT-NM organisations and the AES.

AMWA - The AMWA is the recognized authority focused on the creation of networked media open specifications that enable fully automated, virtualized media workflows.

EBU - The European Broadcasting Union (EBU) is the world’s leading alliance of public service media (PSM). Their members operate nearly 2,000 television and radio channels together with numerous online platforms. The EBU offers technical expertise, advocacy, guidance, tools and recommendations to its members.

IABM - IABM is the only international trade association for suppliers of broadcast and media technology. IABM supports member companies with a comprehensive range of services across market intelligence, training, events, technology, exhibitions, business standards and best practices.

MNA – The Media Networking Alliance is a non-profit organization formed to actively promote the adoption of the AES67 audio networking interoperability standard.

SMPTE® - For more than a century, the people of SMPTE (pronounced “simp-tee”) have sorted out the details of many significant advances in media and entertainment technology, from the introduction of ‘talkies’ and colour television to HD and UHD (4K, 8K) TV. Since its founding in 1916, SMPTE has received an Oscar® and multiple Emmy® Awards for its work in advancing moving-imagery engineering across the industry. SMPTE has developed thousands of standards, recommended practices and engineering guidelines, more than 800 of which are currently in force today. SMPTE Time Code™ and the ubiquitous SMPTE Colour Bars™ are just two examples of SMPTE’s notable work. As it enters its second century, SMPTE is shaping the next generation of standards and providing education for the industry to ensure interoperability as the evolution into IT- and IP-based workflows continues.

The Video Services Forum (VSF) - The Video Services Forum (VSF) is an international association comprised of service providers, users and manufacturers dedicated to interoperability, quality metrics and education for video networking technologies. For many years, the VSF has been active in developing video over IP technical recommendations and conducting interoperability testing for its member companies. A number of these recommendations are being demonstrated in the IBC Showcase..

Contact information

Bubble Communications
Louise Wells
E: louisew@bubbleagency.com
T: +44 7718 985 252

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third